LNSR
LENSAR, Inc.
There isn't enough reported data to score LNSR yet.
NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
LNSR Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Unavailable | |
| Strong |
LNSR's revenue and balance sheet are currently healthy, but its profitability is under pressure. There isn't enough data to rate its cash flow.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
LNSR PE Valuation
LNSR has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
LNSR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Growth | |
| Strongly weakening | |
| Limited | |
| Moderate |
Analysts expect LNSR's losses to grow, with revenue growing.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
NVO has the edge over LNSR on the outlook, with more favorable earnings expectations.
LNSR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | -$2.87 | -$0.14 |
| Q3 2025 | -$4.40 | -$2.96 |
| Q2 2025 | -$4.22 | -$2.68 |
| Q1 2025 | -$4.86 | -$3.30 |
| Q4 2024 | -$2.73 | -$0.96 |
| Q3 2024 | -$1.44 | +$0.23 |
| Q2 2024 | -$1.54 | +$0.29 |
| Q1 2024 | -$1.56 | +$0.13 |
NVO has the stronger earnings trend. Trailing diluted EPS is down 205% for LNSR versus NVO up 4.9%.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO's earnings per share have climbed steadily: $3.89 over the past year, up 4.9% from the year before, and higher year over year every quarter since late 2020.
LNSR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $14.1M | -1.3% |
| Q2 2026 | $16.5M | +18% |
| Q1 2026 | $13.4M | -5.2% |
| Q4 2025 | $16M | -4.2% |
| Q3 2025 | $14.3M | +5.7% |
| Q2 2025 | $13.9M | +10% |
| Q1 2025 | $14.2M | +34% |
| Q4 2024 | $16.7M | +38% |
LNSR's revenue fell from its 2024 peak and has held roughly level since: $14M last quarter, down 1.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -10% | +43 points |
| Q2 2026 | 13% | +58 points |
| Q1 2026 | 17% | +58 points |
| Q4 2025 | -31% | -23 points |
| Q3 2025 | -53% | -44 points |
| Q2 2025 | -45% | -3.3 points |
| Q1 2025 | -41% | -14 points |
| Q4 2024 | -7.7% | +17 points |
LNSR's operating margin was −10% last quarter, up 43 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over LNSR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over LNSR on profitability, with a higher operating margin.
LNSR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$978K | +$2.5M |
| Q4 2025 | $618K | -83% |
| Q3 2025 | -$3.5M | -212% |
| Q2 2025 | -$5.1M | -$1.2M |
| Q1 2025 | -$6.9M | -$1.6M |
| Q4 2024 | $3.7M | +$4.2M |
| Q3 2024 | $3.1M | +$3.5M |
| Q2 2024 | -$3.9M | -$1.6M |
LNSR has the stronger cash trend. Its trailing FCF is up 22% versus its history, compared with NVO at down 14%.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
LNSR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -46% | -10.6M shares |
| 1 year | +3.9% | +461K shares |
| 3 years | +15% | +1.6M shares |
| 5 years | +33% | +3.1M shares |
| Available history | +17% | +1.8M shares |
LNSR has 12M diluted shares, up 3.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over LNSR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
LNSR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.3x | Net Cash |
LNSR has the edge over NVO on leverage, with a lower net debt burden relative to earnings.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
LNSR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.2 | Neutral |
| Stochastic | 12.6 | Oversold |
LNSR's weekly RSI is 34 (neutral) and its Stochastic is 13 (oversold).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
LNSR PE vs Healthcare Sector
LNSR has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
LNSR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.99 | 22% below |
| 20 week MA | $6.56 | 28% below |
| 50 week MA | $7.88 | 40% below |
| 100 week MA | $10.0 | 53% below |
| 200 week MA | $6.92 | 32% below |
LNSR is in a downtrend: it's below all five of its weekly moving averages, and 32% below its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over LNSR on trend strength, trading above more of its moving averages.
LNSR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.00 | $6.86 | -24% |
| 2021 | $6.86 | $6.00 | -13% |
| 2022 | $6.00 | $2.77 | -54% |
| 2023 | $2.77 | $3.51 | +27% |
| 2024 | $3.51 | $8.38 | +139% |
| 2025 | $8.38 | $12.0 | +43% |
| 2026 YTD | $12.0 | $4.70 | -61% |
LNSR's yearly returns have swung widely, from +139% in 2024 to −54% in 2022. It's down 61% so far in 2026.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over LNSR on returns for 2026, with the stronger performance.